Spero Therapeutics Overview
- Year Founded
-
2013
- Status
-
Public
- Employees
-
46
- Stock Symbol
-
SPRO
- Investments
-
3
- Share Price
-
$1.29
- (As of Thursday Closing)
Spero Therapeutics General Information
Description
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Contact Information
Website
www.sperotherapeutics.comCorporate Office
- 675 Massachusetts Avenue
- 14th Floor
- Cambridge, MA 02139
- United States
Corporate Office
- 675 Massachusetts Avenue
- 14th Floor
- Cambridge, MA 02139
- United States
Spero Therapeutics Timeline
Spero Therapeutics Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.29 | $1.31 | $0.99 - $1.89 | $69.7M | 54M | 116K | $0.34 |
Spero Therapeutics Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | (6,844) | (10,085) | 46,028 | 401,320 |
| Revenue | 105,428 | 96,735 | 48,579 | 3,070 |
| EBITDA | 15,683 | 21,834 | (44,047) | (87,516) |
| Net Income | 17,455 | 22,806 | (46,415) | (89,756) |
| Total Assets | 149,881 | 182,390 | 124,802 | 171,072 |
| Total Debt | 4,938 | 5,543 | 6,647 | 7,335 |
Spero Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Spero Therapeutics Comparisons
Industry
Financing
Details
Spero Therapeutics Competitors (37)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Melinta Therapeutics | Private Equity-Backed | Parsippany, NJ | ||||
| Incyte | Formerly VC-backed | Wilmington, DE | ||||
| BioVersys | Venture Capital-Backed | Basel, Switzerland | ||||
| Achaogen | Formerly VC-backed | South San Francisco, CA | ||||
| NovaBiotics | Venture Capital-Backed | Aberdeen, United Kingdom |
Spero Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Spero Therapeutics Patents
Spero Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3236710-A1 | Human efficacious dose and dosage schedule of spr720 | Pending | 26-Oct-2021 | ||
| EP-4422616-A1 | Human efficacious dose and dosage schedule of spr720 | Pending | 26-Oct-2021 | ||
| US-20220142986-A1 | High dosage tebipenem pivoxil tablet formulation | Active | 11-Nov-2020 | ||
| AU-2021378320-A1 | High dosage tebipenem pivoxil tablet formulation | Pending | 11-Nov-2020 | ||
| CA-3201497-A1 | High dosage tebipenem pivoxil tablet formulation | Pending | 11-Nov-2020 | A61K9/2054 |
Spero Therapeutics Executive Team (21)
| Name | Title | Board Seat |
|---|---|---|
| Satyavrat Shukla | Board Member, Chief Executive Officer & President | |
| Esther Rajavelu | Chief Financial Officer, Finance & Chief Accounting Officer, Accounting | |
| Timothy Keutzer | Chief Operating Officer, Operations | |
| James Brady | Chief Human Resources Officer | |
| Laurence Rahme Ph.D | Scientific Founder |
Spero Therapeutics Board Members (18)
| Name | Representing | Role | Since |
|---|---|---|---|
| Ankit Mahadevia MD | Self | Chairman | |
| Cynthia Smith | Self | Board Member | |
| Frank Thomas | Self | Board Member | |
| Jean-Francois Formela MD | Atlas Venture | Board Member | |
| John Pottage Jr. | Self | Board Member |
Spero Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Spero Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Spero Therapeutics Investments (3)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Pro Bono Bio (next generation set of antibacterial candidates) | 31-Jan-2017 | Buildings and Property | |||
| Vertex Pharmaceuticals (Novel Gyrase Inhibitors) | 25-May-2016 | Buildings and Property | |||
| Biota Pharmaceuticals (Antibiotics Assets) | 17-Mar-2016 | Corporate Asset Purchase | Buildings and Property |
Spero Therapeutics ESG
Risk Overview
Risk Rating
Updated August, 30, 2022
29.27 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,912
Rank
Percentile
Pharmaceuticals
Industry
of 965
Rank
Percentile
Biotechnology
Subindustry
of 443
Rank
Percentile
Spero Therapeutics FAQs
-
When was Spero Therapeutics founded?
Spero Therapeutics was founded in 2013.
-
Who is the founder of Spero Therapeutics?
Laurence Rahme Ph.D is the founder of Spero Therapeutics.
-
Who is the CEO of Spero Therapeutics?
Satyavrat Shukla is the CEO of Spero Therapeutics.
-
Where is Spero Therapeutics headquartered?
Spero Therapeutics is headquartered in Cambridge, MA.
-
What is the size of Spero Therapeutics?
Spero Therapeutics has 46 total employees.
-
What industry is Spero Therapeutics in?
Spero Therapeutics’s primary industry is Biotechnology.
-
Is Spero Therapeutics a private or public company?
Spero Therapeutics is a Public company.
-
What is Spero Therapeutics’s stock symbol?
The ticker symbol for Spero Therapeutics is SPRO.
-
What is the current stock price of Spero Therapeutics?
As of 03-Oct-2024 the stock price of Spero Therapeutics is $1.29.
-
What is the current market cap of Spero Therapeutics?
The current market capitalization of Spero Therapeutics is $69.7M.
-
What is Spero Therapeutics’s current revenue?
The trailing twelve month revenue for Spero Therapeutics is $105M.
-
Who are Spero Therapeutics’s competitors?
Melinta Therapeutics, Incyte, BioVersys, Achaogen, and NovaBiotics are some of the 37 competitors of Spero Therapeutics.
-
What is Spero Therapeutics’s annual earnings per share (EPS)?
Spero Therapeutics’s EPS for 12 months was $0.34.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
